short-right-arrow logoMobile media-pie 1 7 % share download email linkedin round-download

Privacy Preference Centre

Your Privacy

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. We use two types of cookies on our website: cookies which are necessary for this website to function and analytics cookies. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies used

  • CookieNotice
  • CookieAnalytics

Analytics Cookies

These are Google Analytics cookies which allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site and social media platforms All information these cookies collect is aggregated and therefore anonymous. This cookie is defaulted to ‘Active’, which means we will be able to track, on any anonymous basis, how many visitors we have to our site, and monitor its performance. If you wish to turn them off you can do so by unticking ‘Active’ and clicking ‘Save and Accept Cookies’. For more information on how these cookies work, including a link through to the Google Privacy Policy which sets out further information about data which Google may collect in the course of providing us with Analytics.

Cookies used

  • _ga

Targeting Cookies

We use necessary cookies to make our site work. We also use analytics cookies which collect information about how visitors use our website and help us to improve it; these are defaulted to ‘Active’, if you wish to turn them off you can do so through the Cookie Settings. Please be aware that by blocking some types of cookies it may impact your experience of the site and the services we are able to offer. For more information about any of these cookies and our use of them, or to change your settings at any time, please see Cookie Settings and our Cookies Policy.

Bridgepoint in the News

09 October 2018

Bridgepoint acquires HTL from Naxicap

October 8, 2018 – International private equity group Bridgepoint has acquired a majority stake in HTL, a specialist in the manufacture, marketing and innovation of hyaluronic acid (HA) and its by-products, from Naxicap. Naxicap will reinvest via a significant minority interest. Terms of the transaction have not been released.

Working with the management team and Naxicap, Bridgepoint intends to support HTL's international expansion and external growth strategy.

Created in 1992, HTL is based in Fougères (Ille-et-Vilaine, Brittany) and specializes in the manufacture and purification of hyaluronic acid. It has since diversified into research and development covering other biological polymers for the pharmaceutical and medical fields. HTL stands out from the competition because of its ability to obtain HA with an ultra-high molecular weight, which adds stability and effectiveness for injectable products prepared in the fields of ophthalmology, rheumatology or dermatology. It is also one of the few global manufacturers that can produce a significant volume of pharmaceutical quality HA. Many of the company's clients believe that HTL products offer the best quality on the market.

Managed by CEO Yvon Bastard and his team, the company now has over 110 employees and hopes to boost hiring. To further its expertise, HTL relies on its R&D department, which is dedicated to the production of new HA bi-products in four specialized laboratories.

HTL also wishes to accelerate its international development. To date, about 90% of the production is sold in Europe, of which approximately 25% in France. With its market leadership and loyal client base, HTL is perfectly positioned to pursue its robust growth.

Vincent-Gael Baudet, a Bridgepoint partner in Paris, commented: "We are pleased to partner with HTL, a company whose profile is very much in line with the investments we support. In the healthcare field, a sector where Bridgepoint's expertise is recognised, HTL enjoys a leading position in a high-growth market, with positive momentum in terms of supply and demand and unparalleled product quality. This is thanks to the remarkable drive of the management team and Naxicap. Our international network will be able to assist HTL with its global development, particularly in Asia and in North America, where we are already present."

HTL CEO Yvon Bastard added: "HTL is a world leader in the HA and by-products markets. Since 2017, Naxicap has provided outstanding support in the development, structuring and investments necessary to back our organic growth ambitions. The HTL management team will be supported by Bridgepoint's experience and global network to accelerate its international development strategy and its positioning in terms of new therapies, while reinforcing its base with historical partners. The HTL employees are all proud of the work accomplished over the last 18 months and are eagerly looking forward to this new phase of development."

Eric Aveillan, Naxicap Partners Managing Partner, continued: "We acquired HTL in February 2017 from the founding family as part of a Management Buy-In. During these first 18 months, the HTL teams have been able to unleash their potential and leverage their remarkable expertise thanks to the appointment of a new CEO (Mr. Yvon Bastard), the company's professionalization and an ambitious investment and recruitment policy. The company has resumed growth, reporting a substantial revenue increase in the last fiscal year, thereby consolidating its position as sector leader. The arrival of a recognized shareholder such as Bridgepoint demonstrates the quality of the project and follows the long-term industrial interest of the company whose future growth is now primarily international."

Current and past healthcare companies in Bridgepoint portfolios include Acteon, Care UK, Diaverum, Médipôle Partenaires, C2S Group and BALT (interventional neuroradiology).


Contact us

If you are interested in working for Bridgepoint, please complete the form below.


Investor reports registration

To access investor reports through the web based reporting facility, please fill in the form to register for an account.

The information submitted on this form will be used for the sole purpose of registering you as an account user and will not be shared with third parties.


Request a copy of The Point

Mandatory fields are marked as (required*)